These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36149907)

  • 41. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
    Tunis SL; Minshall ME; Conner C; McCormick JI; Kapor J; Yale JF; Groleau D
    Curr Med Res Opin; 2009 May; 25(5):1273-84. PubMed ID: 19366302
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy.
    Owens DR; Traylor L; Mullins P; Landgraf W
    Diabetes Res Clin Pract; 2017 Feb; 124():57-65. PubMed ID: 28092788
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial.
    Rosenstock J; Fonseca V; Schinzel S; Dain MP; Mullins P; Riddle M
    J Diabetes Complications; 2014; 28(5):742-9. PubMed ID: 24856612
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Real-world Safety and Effectiveness of Insulin Glargine 300 U/mL in Participants with Type 2 Diabetes Mellitus During the Period of Ramadan in Four Countries (Egypt, Jordan, Lebanon, and Turkey): A Prospective Observational Study.
    Hassanein M; Shaltout I; Malek R; Assaad Khalil S; Ballout H; Annabi F; Shereen M
    Curr Diabetes Rev; 2024; 20(5):e110823219694. PubMed ID: 37581325
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The efficacy of insulin degludec and insulin glargine over NPH insulin among toddlers and preschoolers with type 1 diabetes using glycemic variability and time in range.
    Elhabashy SA; Sakr EM; Salah NY
    Eur J Pediatr; 2023 Apr; 182(4):1857-1868. PubMed ID: 36800034
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes.
    Bolli GB; Songini M; Trovati M; Del Prato S; Ghirlanda G; Cordera R; Trevisan R; Riccardi G; Noacco C
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):571-9. PubMed ID: 18676131
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of gender on treatment outcomes in type 2 diabetes mellitus.
    McGill JB; Vlajnic A; Knutsen PG; Recklein C; Rimler M; Fisher SJ
    Diabetes Res Clin Pract; 2013 Dec; 102(3):167-74. PubMed ID: 24183259
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
    Janka HU; Plewe G; Busch K
    J Am Geriatr Soc; 2007 Feb; 55(2):182-8. PubMed ID: 17302653
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [POET2 registry: Comparison of annual direct medical costs of treating type 2 diabetes after addition of insulin NPH or insulin glargine to oral antidiabetic therapy in the Czech Republic].
    Kvapil M; Žďarská DJ; Suchopár J; Prokeš M; Brož J
    Vnitr Lek; 2015 Jan; 61(1):24-32. PubMed ID: 25693613
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypoglycemic events and glycosylated hemoglobin values in patients with type 2 diabetes mellitus newly initiated on insulin glargine or premixed insulin combination products.
    Bullano MF; Fisher MD; Grochulski WD; Menditto L; Willey VJ
    Am J Health Syst Pharm; 2006 Dec; 63(24):2473-82. PubMed ID: 17158695
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and risk of hypoglycemia with use of insulin glargine or comparators in patients with cardiovascular risk factors.
    Blonde L; Baron MA; Zhou R; Banerji MA
    Postgrad Med; 2014 May; 126(3):172-89. PubMed ID: 24918802
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
    Mullins P; Sharplin P; Yki-Jarvinen H; Riddle MC; Haring HU
    Clin Ther; 2007 Aug; 29(8):1607-19. PubMed ID: 17919543
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term efficacy of insulin glargine after switching from NPH insulin as intensive replacement of basal insulin in Japanese diabetes mellitus. Comparison of efficacy between type 1 and type 2 diabetes (JUN-LAN Study 1.2).
    Kanazawa Y; Igarashi Y; Komiya K; Sakurai Y; Shimizu T; Fujitani Y; Tanaka Y; Watada H; Kawamori R; Hirose T
    Endocr J; 2007 Dec; 54(6):975-83. PubMed ID: 18000343
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of switching from NPH insulin to insulin glargine in patients with type 2 diabetes: the retrospective, observational LAUREL study in Italy.
    Bellia A; Babini AC; Marchetto PE; Arsenio L; Lauro D; Lauro R
    Acta Diabetol; 2014 Apr; 51(2):269-75. PubMed ID: 24275956
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Glycemic variability in insulin treated type 2 diabetes with well-controlled hemoglobin A1c and its response to further treatment with acarbose.
    Su JB; Wang XQ; Chen JF; Wu G; Jin Y
    Chin Med J (Engl); 2011 Jan; 124(1):144-7. PubMed ID: 21362322
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.
    Johansen OE; Vanberg PJ; Kilhovd BK; Jørgensen AP
    Vasc Health Risk Manag; 2009; 5(1):121-8. PubMed ID: 19436668
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial.
    Home P; Bartley P; Russell-Jones D; Hanaire-Broutin H; Heeg JE; Abrams P; Landin-Olsson M; Hylleberg B; Lang H; Draeger E;
    Diabetes Care; 2004 May; 27(5):1081-7. PubMed ID: 15111525
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative study between two recombinant human NPH insulin formulations for the treatment of type 2 diabetes mellitus.
    Rassi N; Moraes SM; Alves AG; Cavalheiro DC; Moreira JM; Bellório KB; Abreu FC; Prata PR; Teixeira Lde S; Rassi S
    Arch Endocrinol Metab; 2016 Feb; 60(1):47-53. PubMed ID: 26909482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.